hUC-MSCs + CD19 CAR-T cells

This is a combination cell therapy consisting of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and CD19-targeted chimeric antigen receptor T (CAR-T) cells. - **CD19 CAR-T Cells** are genetically engineered T lymphocytes that express a synthetic receptor targeting the B-cell surface protein CD19, leading to direct recognition and killing of malignant B-cells. This approach has transformed treatment for B-cell malignancies such as lymphoma and leukemia by enabling the immune system to specifically target cancerous B-cells[1][2][3]. - **hUC-MSCs** are multipotent stromal cells derived from human umbilical cords, known for their immunomodulatory properties and potential anti-tumor effects[4]. They may enhance the efficacy or safety profile of CAR-T therapies by modulating immune responses or supporting tissue repair. The combination aims to leverage both targeted cytotoxicity against cancer (via CD19 CAR-T) and supportive immunomodulation or tumor microenvironment modification (via hUC-MSCs). This strategy is under investigation primarily for relapsed/refractory B-cell malignancies.

Other names

hUC-MSCs + CD19 CAR-T cellshuman umbilical cord-derived mesenchymal stem cells plus CD19 chimeric antigen receptor T cells